Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10410629" target="_blank" >RIV/00216208:11110/20:10410629 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/20:10410629
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=VBXPncHaI-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=VBXPncHaI-</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1358/dof.2020.45.2.3058863" target="_blank" >10.1358/dof.2020.45.2.3058863</a>
Alternative languages
Result language
angličtina
Original language name
Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy
Original language description
Treatment of glomerular diseases remains challenging. There are limited therapeutic options currently available for focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN) and they are generally ineffective in a substantial proportion of patients who progress to end-stage kidney disease during long-term follow-up. Standard management involving renin-angiotensin-aldosterone system (RAAS) inhibitors, corticosteroids and various immunosuppressive therapies does not always achieve sustained, complete or partial remission for most patients while causing serious or intolerable adverse effects. There is a substantial unmet need for new treatments to improve outcomes. Sparsentan, a first-in-class, orally active compound combining angiotensin II type 1 (AT1) receptor blockade with endothelin ETA receptor antagonism, offers an innovative dual mechanism of action approach to the treatment of these diseases with a potentially greater nephroprotective effect, compared to RAAS or endothelin inhibition alone. We summarize the molecular and pharmacological features of sparsentan and discuss ongoing clinical trials in FSGS and IgAN. These trials were designed to examine the long-term antiproteinuric effect, nephroprotective potential and safety profile of sparsentan. We also highlight new efforts to evaluate sparsentan in the treatment of Alport syndrome. This review aims to elucidate the potential role of this novel agent in the management of glomerular diseases.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Drugs of the Future
ISSN
0377-8282
e-ISSN
—
Volume of the periodical
45
Issue of the periodical within the volume
2
Country of publishing house
ES - SPAIN
Number of pages
20
Pages from-to
79-98
UT code for WoS article
000518209600001
EID of the result in the Scopus database
2-s2.0-85085623463